New data for Roche’s Ocrevus show benefit in disability progression and cognitive decline in secondary progressive and primary progressive multiple sclerosis Read more
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS Read more